MarginsXMarginsX
Home › Markets › Health Care › QDEL

QuidelOrtho Corporation (QDEL)

QDEL trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$10.21
-4.93% on the day
Market cap
$700.5M
Small cap
Revenue · 2025
$2.7B
-1.9% on 2024
Net income · 2025
-$1.1B
-41.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-28, https://www.sec.gov/Archives/edgar/data/1906324/000190632426000008/0001906324-26-000008-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-28.

Profile

FieldValue
TickerQDEL on Nasdaq
SectorHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001906324
SEC industry codeIn Vitro & In Vivo Diagnostic Substances

Financials · 2025

LineValue
Revenue$2.7B
Net income-$1.1B
Operating income-$919.2M
Net margin-41.5%
Operating margin-33.7%
Revenue growth-1.9%
Cash$169.8M
Total assets$5.8B
P/E (computed)Net income was not positive
P/S (computed)0.3×

Warning signs

Cash runway
Cash-flow positive
$166.4M cash at September 27, 2026
Share count, 1 year
+1.0%
2025-10-29 to 2026-10-28 · +2.7% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
$1.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$166.4M cash; operating cash flow $2.0M a quarter.Report 2026-09-27
Shares outstanding68,612,588 (2026-10-28); 67,931,540 a year earlier; 66,818,718 three years earlier.Cover page 2026-10-28
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Short Hills, New Jersey, United States; changed auditors 1 time in 24 months8-K 4.01 2025-03-04
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $1.2M, sold $112K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-27
$618.9M-$53.8M$19.6M$166.4M$2.9B$2.6B10-Q 2026-11-04
Q2 2026
2026-06-28
$630.9M-$92.9M-$110.6M$123.4M$2.9B$2.7B10-Q 2026-08-07
Q1 2026
2026-03-29
$619.8M-$91.8M-$33.0M$140.4M$2.7B$2.7B10-Q 2026-05-06
Q4 2025
2025-12-28
$723.6M-$130.7M$131.9M$169.8M$2.7B$2.7B10-K 2026-02-19
Q3 2025
2025-09-28
$699.9M-$733.0M-$45.5M$98.1M$2.7B$2.7B10-Q 2026-11-04
Q2 2025
2025-06-29
$613.9M-$255.4M-$46.8M$151.7M$2.6B$2.7B10-Q 2026-08-07
Q1 2025
2025-03-30
$692.8M-$12.7M$65.6M$127.1M$2.5B$2.8B10-Q 2026-05-06
Q4 2024
2024-12-29
$707.8M-$178.4M$63.7M$98.3M$2.5B$2.8B10-K 2026-02-19

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32024-11-20
Latest annual report10-K2026-02-19
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-03
Latest proxyDEFA14A2026-04-27

Source: SEC EDGAR submissions feed, 504 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.4%
1 month-23.8%
3 months-28.8%
Year to date-62.4%
1 year-51.6%
From 52-week high-69.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances

TickerCompanyPriceDayMarket cap
QUITAchieve Life Sciences Inc. Common Shares$6.06-4.11%$666.8M
NNNNAnbio Biotechnology$3.88+1.57%$558.3M
MYGNMyriad Genetics Inc.$5.57-1.59%$534.3M
TKNOAlpha Teknova Inc.$7.77-5.36%$488.8M
NTLAIntellia Therapeutics Inc.$9.86+1.65%$1.4B
CLDXCelldex Therapeutics Inc.$28.59-0.83%$2.2B
NEOGNeogen Corporation$10.88-3.12%$2.4B
ICCCImmuCell Corporation$11.42+6.23%$103.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier